AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 CytokineticsFrequency TherapeuticsPhoenix TreeGossamer BioAprea Therapeutics
SymbolNASDAQ:CYTKNASDAQ:FREQNASDAQ:IMABNASDAQ:GOSSNASDAQ:APRE
Price Information
Current Price$20.72$18.56$24.93$12.15$26.86
52 Week RangeBuyBuyBuyBuyBuy
Beat the Market™ Rank
Overall Score1.81.51.01.41.3
Analysis Score4.53.31.53.53.3
Community Score3.52.63.62.42.2
Dividend Score0.00.00.00.00.0
Ownership Score1.01.00.01.01.0
Earnings & Valuation Score0.00.60.00.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$26.43$28.50$17.34$29.29$37.25
% Upside from Price Target27.55% upside53.56% upside-30.45% downside141.03% upside38.68% upside
Trade Information
Market Cap$1.23 billion$562.27 million$1.38 billion$801.63 million$541.53 million
Beta1.31N/AN/A1.21N/A
Average Volume939,891136,29293,615531,68981,139
Sales & Book Value
Annual Revenue$26.87 million$28.95 million$4.31 millionN/AN/A
Price / Sales45.8619.88330.05N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value($0.77) per share$5.32 per shareN/A$4.62 per share$5.38 per share
Price / Book-26.913.49N/AN/A
Profitability
Net Income$-121,690,000.00$-18,750,000.00N/A$-180,310,000.00$-28,060,000.00
EPS($2.11)($2.29)($28.90)($3.29)($4.67)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/A80.70N/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-592.61%N/AN/AN/AN/A
Return on Equity (ROE)-10,351.99%N/AN/A-53.83%N/A
Return on Assets (ROA)-56.54%N/AN/A-45.47%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.01%N/A0.12%N/A
Current Ratio10.89%4.80%N/A12.53%10.79%
Quick Ratio10.89%4.80%N/A12.53%10.79%
Ownership Information
Institutional Ownership Percentage93.71%40.75%8.15%58.13%63.84%
Insider Ownership Percentage6.40%N/AN/A23.30%N/A
Miscellaneous
Employees1303318511814
Shares Outstanding59.47 million31.01 million57.06 million66.36 million21.06 million
Next Earnings Date8/13/2020 (Estimated)8/13/2020 (Estimated)N/A8/13/2020 (Estimated)8/21/2020 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.